THE FUTURE
Optimizing treatment with improved delivery and improved cannabinoids.
Cannabis and cannabis extracts have poor bioavailability – the great majority of the active components never reach the systemic bloodstream, resulting in far higher costs to the patient or consumer than is necessary, and too much variability in effect from dose to dose and person to person. Extracts also limit the patient to receiving mixtures of multiple cannabinoids and other active species according entirely to what is present in available strains of plant, rather than the specific cannabinoid or specific mixture best suited to the particular need.
The future is in improved delivery of cannabinoids providing higher bioavailability, and tailored combinations of cannabinoids and natural actives according to the need of the patient or supplement consumer.
OF CBD
